Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
Enric DomingoCaroline A KellyJennifer HayOwen SansomNoori MakaKarin OienTimothy J IvesonMark SaundersRachel KerrIan TomlinsonJoanne EdwardsAndrea HarkinMarta NowakViktor Hendrik KoelzerAlistair EastonIoannis BoukovinasEleni MoustouIppokratis MessaritakisMaria ChondrozoumakiMichaela KaragianniFranck PagèsFanny ArnouxChristelle LautardYoann LoveraIsabelle BoquetAurelie CatteauJerome Galonnull nullIoannis SouglakosDavid N ChurchPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
IS is prognostic in stage III CRC treated with FOLFOX or CAPOX, including within clinically relevant tumor subgroups. Possible variation in IS prognostic value by age and MMR status, and prediction of benefit from extended adjuvant therapy merit validation.